Sponsor: University of Oxford

Study Status

Target recruitment: Approx. 40 patients

Recruitment Period: 18 months from November 2014

Trial Treatment

Patients are allocated to one of three treatment arms

All patients either have surgery or a biopsy before and after six weeks exposure to either mifamurtide alone, Ifosfamide alone, or mifamurtide combined with Ifosfamide. Further treatment to a maximum of 36 or 42 weeks in total, with all patients being able to receive 36 weeks of mifamurtide treatment.


​Sponsor: University of Oxford
EudraCT number: 2012-000616-28

Eurosarc Trial of Linsitinib in advanced Ewing Sarcoma

Study Status

Closed to recruitment

This is a multi-centre, single arm Phase II study, utilising Bayesian analysis


Sponsor: University of Oxford
EudraCT number: 2011-003169-13

A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma

Further information about this trial can be found on the CRUK website.


Sponsor: University of Oxford
EudraCT number: 2012-003762-40

A CR-UK phase I study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy.

To determine the safety, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of BKM120 when administered concomitantly with thoracic radiotherapy in patients with metastatic NSCLC.

Study Status

Completed recruitment. Many thanks to the trial team at the Churchill Hospital for their hard work during the trial.


Sponsor: University of Oxford
Clinical Number: NCT02145416

Anal squamous cell carcinoma: Investigation of functional imaging during Chemoradiotherapy (CRT)

Study Design

A single centre observational study to evaluate changes in functional images (MRI, Perfusion - CT, & FDG PET) after treatment with chemoradiotherapy.

Study Population

Patients undergoing radical CRT for anal cancer in Oxford University Hospitals NHS Trust.


About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.
Subscribe to Department of Oncology RSS